The Effect of Poria cocos Extract to Inhibit Enterovirus Replication

적복령 추출물의 심근염 유발 엔테로바이러스 증식 억제 효과

  • Han, Jae-Young (Department of Biomedical Science, Jungwon University) ;
  • Kim, Jin Hee (College of Herbal Bio-industry, Daegu Haany University) ;
  • Lim, Byung-Kwan (Department of Biomedical Science, Jungwon University)
  • 한재영 (중원대학교 의생명과학과) ;
  • 김진희 (대구한의대학교 한방산업대학) ;
  • 임병관 (중원대학교 의생명과학과)
  • Received : 2016.02.11
  • Accepted : 2016.05.13
  • Published : 2016.06.30


Enterovirus is a common cause of several severe diseases such as myocarditis, hand-foot-mouth disease, and meningitis in children and adult. There are many try to develop new antiviral drug for direct treatment in virus infection. However, synthetic chemical antiviral drug is not working. To overcome this limitation, we examined plant extracts. The antiviral effect of plant extracts was screened by HeLa cell survival assay in coxsackievirus B3 (CVB3) infection. We observed a strong antiviral effect of Poria cocos extract in a dose-dependent manner (1 mg/ml~0.01 mg/ml). P. cocos extract (1 mg/ml) treatment was dramatically decreased virus protease 2A induced eIF4G-I cleavage and virus capsid protein VP1 production. CVB3 positive and negative strand RNA amplification were significantly reduced in P. cocos extract treatment. P. cocos extract completely blocked early time activation of ERK and AKT activity in CVB3 infection. Taken together these data indicate that the treatment of P. cocos extract strongly inhibit CVB3 replication. Poria cocos extract may possible to developed as a therapeutic agent for enterovirus.



  1. Feldman, A. M. and McNamara, D. (2000) Myocarditis. N. Engl. J. Med. 343: 1388-1398.
  2. Lim, B. K., Xiong, D., Dorner A., Youn, T. J., Yung, A., Liu, T. I., Gu, Y., Dalton, N. D., Wright, A. T., Evans, S. M., Chen, J., Peterson, K. L., McCulloch, A. D., Yajima, T. and Knowlton, K. U. (2008) Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart. J. Clin. Invest. 118: 2758-2770.
  3. Knowlton, K. U., Jeon, E. S., Berkley, N., Wessely, R. and Huber, S. (1996) A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 70: 7811-7818.
  4. Knowlton, K. U. and Badorff, C. (1999) The immune system in viral myocarditis: maintaining the balance. Circ. Res. 85: 559-561.
  5. Xiong, D., Yajima, T., Lim, B. K., Stenbit, A., Dublin, A., Dalton, N. D., Summers-Torres, D., Molkentin, J. D., Duplain, H., Wessely, R., Chen, J. and Knowlton, K. U. (2007) Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 115: 94-102.
  6. Chen, Y. C., Yu, C. K., Wang, Y. F., Liu, C. C., Su, I. J. and Lei, H. Y. (2004) A murine oral enterovirus 71 infection model with central nervous system involvement. J. Gen. Virol. 85: 69-77.
  7. Chen, Z., Sun, H., Yan, Y., Wang, Y., Zhu, C., Zhou, W., Huang, L., Wang, M., Mize, M., Tian, J. and Ji, W. (2015) Epidemiological profiles of hand, foot, and mouth disease, including meteorological factors, in Suzhou, China. Arch. Virol. 160: 315-321.
  8. Wang, S. M. and Liu, C. C. (2014) Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine. Expert Rev Anti Infect Ther. 12: 447-456.
  9. Chen, T. C., Weng, K. F., Chang, S. C., Lin, J. Y., Huang, P. N. and Shih, S. R. (2008) Development of antiviral agents for enteroviruses. J. Antimicrob. Chemother. 62: 1169-1173.
  10. Racaniello, V. R. Chapter24, The picornaviridae; The Viruses and Their Replication. Fields. Virology. (2007).
  11. Huber, S. A. and Lodge, P. A. (1986) Coxsackievirus B-3 myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice. Am. J. Pathol. 122: 284-291.
  12. Lim, B. K., Choi, J. H., Nam, J. H., Gil, C. O., Shin, J. O., Yun, S. H., Kim, D. K. and Jeon, E. S. (2006) Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. Cardiovasc Res. 71: 517-526.
  13. Lim, B. K. and Kim, J. H. (2014) ORI2 inhibits coxsackievirus replication and myocardial inflammation in experimental murine myocarditis. Biol. Pharm. Bull. 37: 1650-1654.
  14. Lim, B. K., Yun, S. H., Ju, E. S., Kim, B. K., Lee, Y. J., Yoo, D. K., Kim, Y. C. and Jeon, E. S. (2015) Soluble coxsackievirus B3 3C protease inhibitor prevents cardiomyopathy in an experimental chronic myocarditis murine model. Virus. Res. 199: 1-8.
  15. Lee, S. M., Lee, Y. J., Yoon, J. J., Kang, D. G. and Lee, H. S. (2014) Effect of Poria cocos on puromycin aminonucleoside- induced nephrotic syndrome in rats. Evid. Based. Complement. Alternat. Med. 2014: 570420.
  16. Choi, Y. H. (2015) Induction of apoptosis by an ethanol extract of Poria cocos Wolf. in human leukemia U937 cells. Oncol. Rep. 34: 2533-2540.
  17. Lim, B. K., Choe, S. C., Shin, J. O., Ho, S. H., Kim, J. M., Yu, S. S., Kim, S. and Jeon, E. S. (2002) Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105: 1278-1281.
  18. Yun, S. H., Lee, W. G., Kim, Y. C., Ju, E. S., Lim, B. K., Choi, J. O., Kim, D. K. and Jeon, E. S. (2012) Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. J. Infect. Dis. 205: 491-497.
  19. Pinkert, S., Westermann, D., Wang, X., Klingel, K., Dorner, A., Savvatis, K., Grossl, T., Krohn S., Tschope, C., Zeichhardt, H., Kotsch, K., Weitmann, K., Hoffmann, W., Schultheiss, H. P., Spiller, O. B., Poller, W. and Fechner, H. (2009) Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus- adenovirus receptor. Circulation 120: 2358-2366.